iPS Cells & Regenerative Medicine– category –
-
Curocell’s Rimqarto, South Korea’s First Homegrown CAR-T, Clears Initial Hurdle for National Health Insurance Reimbursement
KBR (Korea Biomedical Review) South Korea Overview Curocell's Rimqarto (anbalcabtagene autoleucel), South Korea's first domestically developed CAR-T cell therapy, has successfully cleared its initial major step towards national health in... -
3D Bioprinting Market Projected to Reach $6.21 Billion by 2030 Driven by Personalized Medicine and Organ Demand
The Business Research Company (via OpenPR) Unknown Overview This article provides an overview of a market research report published by The Business Research Company. The 3D bioprinting market is projected to expand to $6.21 billion by 20... -
Kincell Bio Accelerates Cell Therapy Programs from Clinical Development to Commercialization with Comprehensive CDMO Services
Kincell Bio (company website) USA Overview Kincell Bio offers comprehensive and reliable Contract Development and Manufacturing Organization (CDMO) services, supporting cell therapy programs from early clinical development through commer... -
Overcoming Cell Therapy Manufacturing Bottlenecks: Mandating Closed, Reproducible, and Scalable Production Platforms
Frontiers Switzerland Overview As cell therapy products move towards commercialization, their manufacturing processes pose significant challenges regarding critical quality attributes, patient safety, and commercial viability. Addressing... -
Addressing Bottlenecks in Cell and Gene Therapy Manufacturing: Urgent Need for Quality Control and Supply Chain Optimization
Drug Discovery News USA Overview Cell and gene therapy (CGT) manufacturing faces significant bottlenecks, particularly in autologous cell therapies, due to logistical delays and complex quality control challenges. Frequent issues arise w... -
Sana Biotechnology Advances Phase 1 Clinical Trial for Immunosuppression-Free iPSC-Derived Islet Cell Therapy UP421 for Type 1 Diabetes
AAII USA Overview Sana Biotechnology is actively progressing its Phase 1 clinical trial for UP421, an allogeneic islet cell product engineered with its Hypoimmune Platform (HIP) technology for type 1 diabetes, aiming to eliminate the nee... -
CRISPR Gene Therapies Expand in 2026: EDIT-101 for Retinitis Pigmentosa Gains FDA Accelerated Approval, Following Casgevy for Sickle Cell Disease
Ubie Doctor's Note Japan Overview By 2026, CRISPR-based gene therapies are rapidly expanding, with EDIT-101 for retinitis pigmentosa receiving FDA accelerated approval in late 2025, building on the 2023 approval of Casgevy for sickle cel... -
EU Approves Itvisma: Single-Dose Gene Therapy Redefines SMA Treatment for Broad Patient Population Aged 2+
BioSpace (via Novartis press release) Europe Overview Novartis' gene therapy Itvisma® (onasemnogene abeparvovec) has received European Commission approval for children, adolescents, and adults aged 2 years and older with 5q spinal muscul... -
iPSC-Derived Off-the-Shelf CAR T Therapy FT819 Shows Promising Safety and Efficacy Signals for Treatment-Resistant Systemic Sclerosis at ISSCR 2026
News-Medical.Net - An AZoNetwork Site USA Overview Preliminary clinical data for FT819, an iPSC-derived CAR T-cell therapy targeting treatment-resistant systemic sclerosis, were presented at the ISSCR 2026 Annual Meeting. FT819 is manufa... -
Dual-Target CAR T Therapy for Glioblastoma Drives Broad Immune Activation, NK Cell Response Correlates with Long-Term Survival in Penn Medicine Study
Vertex AI Search USA Overview Researchers at the Perelman School of Medicine and Abramson Cancer Center discovered that direct intra-cerebrospinal fluid (CSF) delivery of a dual-target CAR T-cell therapy induces a broad immune response i...
